Associations of resistin with inflammatory and fibrinolytic markers, insulin resistance, and metabolic syndrome in middle-aged and older Chinese.

OBJECTIVE Resistin increases insulin resistance (IR) in mice. However, the role of resistin in human disease remains controversial. We aimed to assess plasma resistin levels and their associations with inflammatory and fibrinolytic markers, IR and metabolic syndrome (MetS) among Chinese. DESIGN AND METHODS Plasma resistin was measured in a population-based cross-sectional survey of 3193 Chinese aged from 50 to 70 years in Beijing and Shanghai. RESULTS The median resistin concentration was 8.60 ng/ml (interquartile range, 5.78-14.00) among all participants, and it was higher in women than in men (P=0.008). Resistin was correlated weakly with body mass index, waist circumference, high-density lipoprotein (HDL) cholesterol (negatively), homeostatic model assessment of IR and tumor necrosis factor-alpha receptor 2 (TNFR2; r=0.04, 0.07, -0.09 and 0.06 respectively, all P<0.05), and more highly with C-reactive protein (CRP), interleukin (IL)6 and plasminogen activator inhibitor (PAI)1 (r=0.12, 0.12 and 0.21 respectively, all P<0.001), but only HDL cholesterol, CRP, IL6, TNFR2, and PAI1 remained significantly associated with resistin in multiple regression analysis (all P<0.05). Furthermore, elevated resistin levels were associated with the higher prevalence of IR and MetS. However, the significant relationships disappeared after adjustment for inflammatory and fibrinolytic markers especially PAI1. CONCLUSIONS This study suggests that resistin is more strongly associated with inflammatory and fibrinolytic markers than with obesity or IR status. The associations of resistin with IR and MetS could largely be explained by inflammatory and fibrinolytic markers especially PAI1 levels.

[1]  Masato Kasuga,et al.  [Obesity and insulin resistance]. , 2009, Nihon rinsho. Japanese journal of clinical medicine.

[2]  I. Zineh,et al.  Relationship between plasma resistin concentrations, inflammatory chemokines, and components of the metabolic syndrome in adults. , 2008, Metabolism: clinical and experimental.

[3]  O. Franco,et al.  The Association of Depressive Symptoms with Inflammatory Factors and Adipokines in Middle-Aged and Older Chinese , 2008, PloS one.

[4]  O. Franco,et al.  Adiponectin and Metabolic Syndrome in Middle‐aged and Elderly Chinese , 2008, Obesity.

[5]  Xu Lin,et al.  Elevated retinol-binding protein 4 levels are associated with metabolic syndrome in Chinese people. , 2007, The Journal of clinical endocrinology and metabolism.

[6]  O. Franco,et al.  Distributions of C-reactive protein and its association with metabolic syndrome in middle-aged and older Chinese people. , 2007, Journal of the American College of Cardiology.

[7]  L. Risch,et al.  Relationship between glomerular filtration rate and the adipokines adiponectin, resistin and leptin in coronary patients with predominantly normal or mildly impaired renal function. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[8]  G. Norata,et al.  Plasma resistin levels correlate with determinants of the metabolic syndrome. , 2007, European journal of endocrinology.

[9]  M. Päivänsalo,et al.  High plasma resistin level is associated with enhanced highly sensitive C-reactive protein and leukocytes. , 2006, The Journal of clinical endocrinology and metabolism.

[10]  U. Smith,et al.  Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. , 2006, The New England journal of medicine.

[11]  U. Müller-Ladner Faculty Opinions recommendation of Resistin, an adipokine with potent proinflammatory properties. , 2006 .

[12]  F. Lönnqvist,et al.  Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. , 2006, Kidney international.

[13]  R. Krauss,et al.  Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement , 2005, Current opinion in cardiology.

[14]  Fernando Costa,et al.  Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. , 2005, Circulation.

[15]  T. Pischon,et al.  Association of plasma resistin levels with coronary heart disease in women. , 2005, Obesity research.

[16]  Paul Zimmet,et al.  The metabolic syndrome—a new worldwide definition , 2005, The Lancet.

[17]  S. Kahn,et al.  Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans , 2005, Diabetologia.

[18]  Reiko Ohmori,et al.  Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. , 2005, Journal of the American College of Cardiology.

[19]  U. Smith,et al.  Resistin, an Adipokine with Potent Proinflammatory Properties1 , 2005, The Journal of Immunology.

[20]  Anand Rohatgi,et al.  Resistin Is an Inflammatory Marker of Atherosclerosis in Humans , 2005, Circulation.

[21]  R. Eckel,et al.  The metabolic syndrome and inflammation. , 2004, Metabolic syndrome and related disorders.

[22]  C. Mantzoros,et al.  Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. , 2004, Diabetes care.

[23]  B. Courten,et al.  Erratum: High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indians (Diabetes (2004) 53 (1279-1284)) , 2004 .

[24]  P. A. Tataranni,et al.  High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indians. , 2004, Diabetes.

[25]  J. Rood,et al.  Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. , 2004, The Journal of clinical endocrinology and metabolism.

[26]  M. Lazar,et al.  Regulation of Fasted Blood Glucose by Resistin , 2004, Science.

[27]  R. Nagai,et al.  Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. , 2004, Biochemical and biophysical research communications.

[28]  Stephen A. Smith,et al.  Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. , 2003, The Journal of clinical endocrinology and metabolism.

[29]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[30]  R. Considine,et al.  Serum resistin (FIZZ3) protein is increased in obese humans. , 2003, The Journal of clinical endocrinology and metabolism.

[31]  J. Eisen,et al.  Comparative studies of resistin expression and phylogenomics in human and mouse. , 2003, Biochemical and biophysical research communications.

[32]  J. Chan,et al.  Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. , 2003, The Journal of clinical endocrinology and metabolism.

[33]  H. Tilg,et al.  Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. , 2003, Biochemical and biophysical research communications.

[34]  S. Verma,et al.  Resistin Promotes Endothelial Cell Activation: Further Evidence of Adipokine-Endothelial Interaction , 2003, Circulation.

[35]  T. Saruta,et al.  Correlation between serum resistin level and adiposity in obese individuals. , 2003, Obesity research.

[36]  P. Morange,et al.  Plasminogen activator inhibitor‐1, inflammation, obesity, insulin resistance and vascular risk , 2003, Journal of thrombosis and haemostasis : JTH.

[37]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[38]  Z. Bloomgarden,et al.  Inflammation and insulin resistance. , 2003, Diabetes care.

[39]  L. Rossetti,et al.  Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. , 2003, The Journal of clinical investigation.

[40]  Joanna D. Holbrook,et al.  Resistin is expressed in human macrophages and directly regulated by PPARγ activators , 2003 .

[41]  J. Heyn,et al.  Plasma Resistin Levels in Patients with Type 1 and Type 2 Diabetes Mellitus and in Healthy Controls , 2002, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[42]  Bei-fan Zhou Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults--study on optimal cut-off points of body mass index and waist circumference in Chinese adults. , 2002, Biomedical and environmental sciences : BES.

[43]  M. Lazar,et al.  The hormone resistin links obesity to diabetes , 2001, Nature.

[44]  K. Uysal,et al.  Tumor necrosis factor α is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1 , 1999 .

[45]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[46]  B. Howard,et al.  Cross-sectional associations of resistin, coronary heart disease, and insulin resistance. , 2006, The Journal of clinical endocrinology and metabolism.

[47]  T. Funahashi,et al.  Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[48]  H. Minuk,et al.  Metabolic syndrome. , 2005, Journal of insurance medicine.

[49]  K. Park,et al.  Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. , 2004, The Journal of clinical endocrinology and metabolism.

[50]  P. Murdock,et al.  Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. , 2003, Biochemical and biophysical research communications.

[51]  K. Uysal,et al.  Tumor necrosis factor alpha is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1. , 1999, Proceedings of the National Academy of Sciences of the United States of America.